RxDoctor Payments DataLook up a doctor →

Daniel Lee, MD

Neurology · Morehead, KYNPI 1790874626

Payments from drug & device makers

$129,061in general payments, 2019–2025

Across 693 payments — averaging $186.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Catalyst Pharmaceuticals, Inc.$45K
  • Eisai Inc.$26K
  • Avanir Pharmaceuticals, Inc.$23K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$7K
  • Argenx US, Inc.$6K
  • MDD US Operations, LLC$6K
  • plus $16K from 46 others

What the payments were for

  • Consulting fees$5,6356%
  • Speaking & faculty fees$64,44269%
  • Travel & lodging$10,47611%
  • Food & beverage$12,50313%
  • Education$3840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$129,061 in reported general payments places this provider in the 85th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$36,907
Medicare patients
222
Services billed
378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FirdapseAmifampridine Phosphate14$860,590
NortheraDroxidopa13$213,816
NeuproRotigotine23$23,835
Frovatriptan Succinate23$11,111
Lacosamide58$9,983
Dimethyl Fumarate11$8,170
Levetiracetam125$3,228
Entacapone31$2,745
Memantine Hcl129$2,626
Carbidopa-Levodopa ErCarbidopa/Levodopa50$2,591
Carbamazepine ErCarbamazepine40$2,390
Gabapentin191$1,894
Carbidopa-LevodopaCarbidopa/Levodopa99$1,552
Memantine Hcl ErMemantine Hcl11$1,545
Pyridostigmine Bromide28$1,538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Catalyst Pharmaceuticals, Inc.Firdapse$45,088$860,59014 claims
Lundbeck LLCNorthera$2,248$213,81613 claims
UCB, Inc.Neupro$1,488$23,83523 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$181$1,53828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 210 neurology providers in Kentucky.

Other neurology in Morehead

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →